Overview:
Hepatitis B Surface Antigen (HBsAg) Rapid TestIntroduction: The Hepatitis B Surface Antigen (HBsAg) Rapid Test is a diagnostic tool designed to detect HBsAg in whole blood, serum, plasma, or saliva samples, facilitating the screening of hepatitis B virus (HBV) infection. HBV, a major global health concern, causes acute and chronic liver disease, presenting with jaundice, fatigue, and severe complications like cirrhosis or hepatocellular carcinoma if untreated, particularly in endemic regions or among high-risk groups. Per the 2023 World Health Organization guidelines, the test employs immunochromatographic technology, delivering results within 15-20 minutes with high sensitivity and specificity, making it a critical tool for rapid diagnosis in resource-limited settings. This rapid diagnostic falls under virology and targets individuals with liver symptoms or risk factors like blood transfusions, addressing the challenge of early detection to guide antiviral therapy with tenofovir or entecavir and vaccination programs. With morbidity rates elevated due to chronicity, the test supports public health efforts by enabling early case identification, facilitating contact tracing, and reducing transmission. Its multi-sample capability enhances its utility.
Other Names: HBsAg Rapid Test.
FDA Status: FDA approved, CLIA certified for virology, compliant with 2025 standards.
Historical Milestone: Introduced in the 2000s by Abbott, this test advanced HBV detection, providing a rapid alternative to enzyme immunoassays.
Purpose: The test screens for HBsAg to guide hepatitis B diagnosis, assess infection stage, and inform treatment and prevention strategies.
Test Parameters: Presence of Hepatitis B Surface Antigen, detected with high specificity to indicate active infection, typically detectable 1-10 weeks post-exposure and persisting in chronic cases.
Pretest Condition: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report jaundice, fatigue, or risk factors like IV drug use.
Specimen: Whole Blood 2-5 mL, Serum 2-5 mL, Plasma 2-4 mL, Saliva 1-2 mL, collected using sterile EDTA or SST tubes/containers, transported within 24 hours to maintain sample viability.
Sample Stability at Room Temperature: 24 hours with proper handling in a cool environment to preserve antigen integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 24 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: Not recommended, as freezing may denature antigens, increasing the risk of false negatives and compromising diagnostic accuracy.
Medical History: Patients should provide details on jaundice, fatigue, liver disease history, or risk factors like blood exposure, as well as any prior HBV vaccination.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated infection including cancer, benefits of early detection, and minimal discomfort from sample collection.
Procedural Considerations: The test utilizes an immunochromatographic cassette requiring trained personnel to ensure sterile technique, avoid hemolysis or contamination, and interpret results within 15-20 minutes using provided positive and negative controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store test kits according to manufacturer specifications to ensure reliability.
Factors Affecting Result Accuracy: Delays beyond 24 hours, improper storage conditions, cross-contamination with other samples, or early infection before antigen development can affect results. Correlation with HBV DNA or liver function tests is recommended to confirm findings.
Clinical Significance: A positive result indicates hepatitis B infection, necessitating antiviral therapy and public health notification. A negative result may require follow-up testing if symptoms persist, especially if sampled too early.
Specialist Consultation: Hepatologists or infectious disease specialists should be consulted for case management, treatment planning, and coordination with public health authorities.
Additional Supporting Tests: HBV DNA, liver function tests, or HBeAg for confirmation.
Test Limitations: The test may produce false negatives in the window period or false positives due to cross-reactivity, requiring a comprehensive diagnostic approach that includes molecular methods.
References: WHO Guidelines 2023, Journal of Hepatology 2024, Clinical Microbiology Reviews 2025.
